BioCryst reports Q1 EPS 0c, consensus (5c)

Reports Q1 revenue $145.534M, consensus $127.79M. “We started 2025 with another quarter of outstanding performance. ORLADEYO revenue growth was driven by moving ORLADEYO patients from free drug to paid at a much faster rate than we expected, resulting in a substantial increase to our annual guidance as we also move closer to peak sales of $1 billion. This increased financial strength accelerates our path to profitability and enables us to start paying down our debt, while continuing to invest in and advance our pipeline,” said Jon Stonehouse, president and chief executive officer of BioCryst (BCRX).